Sentences with phrase «leading cell therapy»

Dr. Doris A. Taylor, PhD, Hon DSc, FAHA, FACC, Director of Regenerative Medicine Research for the Texas Heart Institute (THI), is one of the world's leading cell therapy and cardiac regeneration scientists.

The 2017 Annual Data Report details industry - specific statistics and trends from more than 850 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide.

It is this level of dedication to responsible medicine with oversight and guidance from some of the world's leading cell therapy researchers and medical professionals which set us apart.

Not exact matches

About Nohla Therapeutics Nohla Therapeutics is a leading developer of off - the shelf cell therapies for the treatment of cancer and other critical diseases.

In a rare appearance Dr. Chandan Sen, Director, OSU Center for Regenerative Medicine & Cell - Based Therapies will explain how this breakthrough came about and how the technology is leading to other medical discoveries and how the principle can be used to generate any tissue out of skin or fat which is abundant in human body.

Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).

A group of the nation's leading cancer research scientists and their Cuban counterparts are exploring how to advance cancer therapy, diagnosis, and prevention, including the use of immunotherapy to harness the body's immune systems to attack and eliminate cancer cells.

PhD funding by the University's Institute for Life Sciences for Catarina kick - started the collaboration between Richard and Rahul at the Institute for Developmental Sciences and us, which otherwise might have been difficult, that has led to exciting results, some stunning images and insight that has the potential to change people's lives using stem cell therapy.»

«Cultural revolution in the study of the gut microbiome: Human gut - on - a-chip technology used to co-culture gut microbiome, human intestinal cells could lead to new therapies for inflammatory bowel diseases.»

Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.

We believe that they will also lead to the development of a whole new range of therapies for neurodegenerative diseases of the central nervous system,» explains corresponding author of the study Jihwan Song, professor and director of Neural Regeneration and Therapy Group at the CHA Stem Cell Institute of CHA University.

Again, using mouse models of glioblastoma — this time created from brain tumor cells that were resistant to the herpes virus — the therapy led to increased animal survival.

A new therapy changes the balance of osteoblasts (pictured here) and fat cells in the bone marrow, leading to stronger bones.

Researchers, led by Joshua Mayourian at the Icahn School of Medicine at Mount Sinai, used mathematical modeling to simulate electrical interactions between these stem cells and heart cells to develop insight into possible adverse effects, as well as to hypothesize new methods for reducing some potential risks of this therapy.

Enabling scientists to grow the stem cells artificially from pluripotent stem cells could also lead to the development of personalized blood therapies, researchers say.

«Due to the inhibitory function of Treg cells, people have been trying to use these cells for therapy in human autoimmune diseases or transplantation,» explains professor Yun Cai Liu, Ph.D., who led the current study.

Professor Ali Tavassoli, who led the study with colleague Dr. Ishna Mistry, explains: «In an effort to better understand the role of HIF - 1 in cancer, and to demonstrate the potential for inhibiting this protein in cancer therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF - 1 inhibiting molecule when placed in a hypoxic environment.

Two of 10 children treated with gene therapy for SCID in a French trial develop leukemia, researchers announced in 2002, and it is discovered that the virus had inserted genes in several unexpected places around the genome, leading the cells to become cancerous.

While the combination of targeted therapies improves patient outcomes, any remaining cancer cells can lead to drug resistance.

For his part, Collins, who has led NIH since 2009 and been kept on by the Trump administration, pointed to an array of promising NIH activities, including the development of new technologies to provide insights into human brain circuitry and function through the Brain Research through Advancing Innovative Neuroethologies (BRAIN initiative) and the use of the gene - editing tool CRISPR - Cas9 to correct mutations and clear the way to develop and test a «curative therapy» for the first molecular disease: sickle cell disease.

Chitayat wonders whether proliferation could proceed in unexpected ways, for example leading to tumors — a worry that cuts across many stem cell therapies.

The new chimera interferes with HER2 and HER3 signaling and ultimately leads to cancer cell death, as shown in the group's recent publication in Molecular Therapy: Nucleic Acids.

Graduate student Walter Chen and postdoctoral researcher Kivanc Birsoy have unraveled how to rescue cells suffering from mitochondrial dysfunction, a finding that may lead to new therapies for this condition.

«There is an unmet need to develop new therapies based on R - CHOP to try to increase the cure rate for diffuse large B - cell lymphoma,» says Patrick Johnston, M.D., Ph.D., a hematologist at Mayo Clinic and lead author.

Sophisticated genetic circuitry spliced into cells could lead to cancer therapies, tissue generation on demand

An international group of leading stem cell researchers has issued a statement that specifies concerns about the development and use of unproven stem cell therapies.

«And, eventually it could lead to the development of cell transplant therapies that restore vision in patients with glaucoma and MS.»

Techniques like that may lead to novel therapies while avoiding the primary downfall of stem cell therapies: the development of tumors.

Studying the vying for nutrients in the cell «will teach us really interesting biology about how the cell senses the presence of a parasite metabolically, and how the cell is able to metabolically respond,» Pernas says — knowledge that could lead to new therapies.

«Breast cancer stem cells pose a serious problem for therapy,» says lead study investigator Gregg Semenza, M.D., Ph.D., the C. Michael Armstrong Professor of Medicine, director of the Vascular Biology Program at the Johns Hopkins Institute for Cell Engineering and a member of the Johns Hopkins Kimmel Cancer Center.

«Single gene encourages growth of intestinal stem cells, supporting «niche» cells, and cancer: Finding in mice could lead to new therapies for damaged organs, cancer.»

Still, by identifying the human hairless gene as an important master switch in regulating cell death in a hair follicle — a discovery that could lead to gene therapies for unwanted hair growth — Christiano emerged as a new star in the field, and a glamorous one.

A better understanding of the battle could lead to new therapies that control an infection by keeping parasites from getting to the cell's nutrients, Pernas says.

Finding may enhance understanding of human embryonic stem cells and lead to better models for regenerative therapies

We hope this leads to the ability to design, study and test new therapies for every patient on their own cells in the lab, leading to new treatments and breakthroughs in personalized medicine for individuals with a variety of lung diseases, including cystic fibrosis,» explained lead author Katherine McCauley, a PhD student at BUSM.

While the disease can take many forms, recent advances have better characterized how lymphoma cells proliferate and interact with other cells and tissues, leading to the development of powerful, targeted therapies with fewer side effects than traditional approaches.

Moreover, her studies are the first to indicate that therapies targeted at controlling the properties of smooth muscle cells within lesions may be highly effective in treating a disease that is the leading cause of death worldwide.

Cancer stem cells are strongly associated with the growth and recurrence of all cancers and are especially difficult to eradicate with normal treatment, which also leads to tumours developing resistance to other types of therapy.

Its president also led an expert panel that examined the controversial cell therapy proposed by Stamina Foundation.

«RYBP would make cancer cells more sensitive to DNA damage, which would make chemo or radiation therapy more effective,» said Mohammad Ali, a postdoctoral fellow and the lead author of the study.

A new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) sheds light on a signaling circuit in cells that drives therapy resistance in prostate cancer.

We have found that exosomes and the cargo they contain are crucial mediators of stem cell - based heart regeneration, and we believe this might lead to an even more refined therapy using the «active ingredient» instead of the entire stem cell,» said Eduardo Marbán, MD, PhD, director of the Cedars - Sinai Heart Institute and a pioneer in developing investigational cardiac stem cell treatments.

«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical School.

After other researchers reported that bone marrow stem cell therapy led to a modest but promising 5 percent improvement in the regeneration of sensory nerve fibers in rats with spinal cord injuries, he performed a critical reality check.

«This could lead to personalized therapy where we can look at how an individual's cells respond to different therapeutic cocktails,» said Mirkin, whose lab developed NanoFlares in 2007.

Further development of the B cell application therapy may lead to novel ways of addressing the pathologies underlying the formation of chronic wounds.»

The researchers conclude this technique could eventually lead to new ways to prepare vast numbers of cells for the coordinated manufacture of gene therapies.

«Patients with non-small cell lung cancer (NSCLC) should receive front line therapy with the anaplastic lymphoma kinase (ALK) inhibitor crizotinib,» said lead author Professor Giorgio Scagliotti, head of the Department of Oncology, University of Turin, Italy.

The findings, published online in the journal Cell, could lead to the first broadly effective ebolavirus therapies and vaccines.

Dr. Cooper joined MDACC in 2006 as section chief of cell therapy at the Children's Cancer Hospital, where he cared for children undergoing bone marrow transplantation and led scientific efforts to develop new treatment approaches that pair genetic engineering with immunotherapies.